Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-1123 in Autosomal Dominant Retinitis Pigmentosa (P23H)
NCT04123626Phase 2Active, not recruiting
- Sponsor
- ProQR Therapeutics
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QR-1123 in Autosomal dominant retinitis pigmentosa (ADRP) (7 arms), sponsored by ProQR Therapeutics. Primary endpoints: Incidence and Severity of ocular Adverse Events at 12 months and Incidence and Severity of non-ocular Adverse Events at 12 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
QR-1123
03
Conditions
Autosomal dominant retinitis pigmentosa (ADRP)
Beyond the preview
Go deeper on NCT04123626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123626.